title: Neuroprotective effect of lutein against 3-nitropropionic acid-induced Huntington's disease-like symptoms: possible behavioral, biochemical, and cellular alterations.
abstract: 3-Nitropropionic acid (3-NP) induces cellular energy deficit and oxidative stress-related neurotoxicity via an irreversible inhibition of mitochondrial complex II enzyme, succinate dehydrogenase. Huntington's disease (HD) is a neurological disorder characterized by cognitive and motor dysfunctions. Lutein is a well-known antioxidant used in the management of oxidative stress related diseases. Clinical trials have supported the beneficial effect of lutein in Alzheimer's disease. The present study was designed to explore possible neuroprotective effects of lutein on 3-NP-induced mitochondrial dysfunction and oxidative stress. Systemic administration of 3-NP (25 mg/kg intraperitoneally [i.p.] for 4 consecutive days) caused loss of body weight and neurobehavioral deficits by hind-limb impairment (Narrow Beam test), motor coordination (locomotor activity) and memory dysfunction (Morris water maze and Elevated Plus maze performance). Biochemical analysis revealed significant increase in lipid peroxidation, nitrite concentration, reduced gutathione levels, and acetyl cholinesterase levels and depleted catalase activities in rat brain. The activities of mitochondrial complexes (I, II, IV, and MTT assay) were found to be significantly lowered in brain mitochondria. Daily lutein (50 or 100 mg/kg orally [p.o.]) administration for 14 days significantly improved body weight, neurobehavioral alterations and attenuated oxidative stress and improved mitochondrial enzymes complex activities of rat brain. Histopathological examination further affirmed the neuroprotective effect of lutein on 3-NP induced pathological lesions. The present study indicates that lutein is a promising candidate for the management of HD and related conditions.
authors.affiliation: Department of Pharmacology, Bombay College of Pharmacy , Mumbai, India .
authors.forename: Yogita
authors.initials: Y
authors.lastname: Binawade
authors.forename: Aarti
authors.initials: A
authors.lastname: Jagtap
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D015227:Lipid Peroxidation; D014975:Lutein / Q000008:administration & dosage*; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009574:Nitro Compounds / Q000009:adverse effects*; D011422:Propionates / Q000009:adverse effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018696:Neuroprotective Agents; D009574:Nitro Compounds; D011422:Propionates; D005978:Glutathione; C015392:3-nitropropionic acid; D014975:Lutein